Kalpit Patel
Stock Analyst at B. Riley Securities
(2.02)
# 3,118
Out of 5,099 analysts
70
Total ratings
43.75%
Success rate
-7.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PDSB PDS Biotechnology | Maintains: Buy | $5 → $3 | $1.06 | +183.02% | 6 | Nov 25, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Peer Perform | n/a | $10.14 | - | 1 | Nov 18, 2025 | |
| CORT Corcept Therapeutics | Initiates: Peer Perform | n/a | $83.15 | - | 1 | Nov 18, 2025 | |
| JANX Janux Therapeutics | Initiates: Peer Perform | n/a | $15.74 | - | 1 | Nov 18, 2025 | |
| TNGX Tango Therapeutics | Initiates: Peer Perform | n/a | $9.12 | - | 1 | Nov 18, 2025 | |
| ACLX Arcellx | Initiates: Peer Perform | n/a | $70.84 | - | 1 | Nov 18, 2025 | |
| SMMT Summit Therapeutics | Initiates: Peer Perform | n/a | $17.02 | - | 1 | Nov 18, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $42 | $44.63 | -5.89% | 1 | Nov 18, 2025 | |
| SLNO Soleno Therapeutics | Initiates: Outperform | $75 | $50.01 | +49.97% | 1 | Nov 18, 2025 | |
| RVMD Revolution Medicines | Initiates: Outperform | $75 | $77.81 | -3.61% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $110 | $102.72 | +7.09% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $8.13 | +47.60% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $60 | $86.88 | -30.94% | 5 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $14 | $7.09 | +97.46% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $24.95 | +48.30% | 1 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $24 | $42.33 | -43.30% | 6 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5.5 → $3.5 | $1.23 | +184.55% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $10.12 | -11.07% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.36 | +129.36% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $40 | $10.10 | +296.04% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $1.57 | +91.08% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $31.80 | -37.11% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $3.64 | +724.18% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $19.51 | +84.52% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $1.70 | +5,194.12% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.42 | +1,167.61% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.10 | +138.10% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $12.99 | +669.82% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $20.09 | +273.32% | 2 | Sep 3, 2021 |
PDS Biotechnology
Nov 25, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.06
Upside: +183.02%
ORIC Pharmaceuticals
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $10.14
Upside: -
Corcept Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $83.15
Upside: -
Janux Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $15.74
Upside: -
Tango Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $9.12
Upside: -
Arcellx
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $70.84
Upside: -
Summit Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $17.02
Upside: -
Scholar Rock Holding
Nov 18, 2025
Initiates: Outperform
Price Target: $42
Current: $44.63
Upside: -5.89%
Soleno Therapeutics
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $50.01
Upside: +49.97%
Revolution Medicines
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $77.81
Upside: -3.61%
Nov 18, 2025
Initiates: Outperform
Price Target: $110
Current: $102.72
Upside: +7.09%
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $8.13
Upside: +47.60%
Jun 3, 2025
Upgrades: Buy
Price Target: $38 → $60
Current: $86.88
Upside: -30.94%
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $7.09
Upside: +97.46%
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $24.95
Upside: +48.30%
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $42.33
Upside: -43.30%
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.23
Upside: +184.55%
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $10.12
Upside: -11.07%
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.36
Upside: +129.36%
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $10.10
Upside: +296.04%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.57
Upside: +91.08%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $31.80
Upside: -37.11%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $3.64
Upside: +724.18%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $19.51
Upside: +84.52%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $1.70
Upside: +5,194.12%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.42
Upside: +1,167.61%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $2.10
Upside: +138.10%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $12.99
Upside: +669.82%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $20.09
Upside: +273.32%